

Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 February 2004 on drug precursors (Text with EEA relevance)

[^{F1}Article 16

Information about measures adopted by Member States

- 1 Member States shall inform the Commission of the measures they adopt pursuant to this Regulation, and in particular of the measures adopted pursuant to Articles 10 and 12. They shall also notify any subsequent amendments thereof.
- 2 The Commission shall communicate that information to the other Member States.
- 3 The Commission shall, by 31 December 2019, submit a report to the European Parliament and to the Council on the implementation and functioning of this Regulation, and in particular on the possible need for additional action to monitor and control suspicious transactions with non-scheduled substances.]

Textual Amendments

- F1** Substituted by [Regulation \(EU\) No 1258/2013 of the European Parliament and of the Council of 20 November 2013 amending Regulation \(EC\) No 273/2004 on drug precursors \(Text with EEA relevance\)](#).

Changes to legislation:

There are outstanding changes not yet made to Regulation (EC) No 273/2004 of the European Parliament and of the Council. Any changes that have already been made to the legislation appear in the content and are referenced with annotations.

[View outstanding changes](#)

Changes and effects yet to be applied to :

- Art. 16 omitted by [S.I. 2019/742 reg. 13\(17\)](#)

Changes and effects yet to be applied to the whole legislation item and associated provisions

- Signature words omitted by [S.I. 2019/742 reg. 13\(18\)](#)
- Art. 2(a) words substituted by [S.I. 2019/742 reg. 13\(3\)\(a\)](#)
- Art. 2(c) words substituted by [S.I. 2019/742 reg. 13\(3\)\(b\)](#)
- Art. 3(8)(c) omitted by [S.I. 2019/742 reg. 13\(4\)\(d\)\(ii\)](#)